**Chemotherapy-unique resistance mechanisms center on drug efflux, metabolism, and target alterations, while radiotherapy-unique mechanisms emphasize DNA repair capacity, cancer stem cell properties, and specific microenvironmental adaptations. **

## Chemotherapy-Specific Resistance Mechanisms

**Drug efflux and metabolism** are hallmark chemotherapy resistance mechanisms. The ATP-binding cassette (ABC) transporter family, particularly **ABCB1 (MDR1/P-glycoprotein)** , actively pumps chemotherapeutic agents out of cancer cells, reducing intracellular drug concentrations.[1][2][3]

Drug-metabolizing enzymes catalyze reactions that inactivate chemotherapeutic drugs, rendering them ineffective.[4]

The **glutathione detoxification system** conjugates with platinum-based drugs, causing insensitivity to these agents.[4] **Drug target alterations** represent another chemotherapy-specific mechanism. Changes in HER2 receptor expression lead to poorer efficacy of HER2 receptor inhibitors.[4]

Mutations in drug targets can render chemotherapeutic agents ineffective at their intended molecular sites.[2] **Epithelial-mesenchymal transition (EMT)** contributes specifically to chemoresistance by altering cellular phenotypes and enhancing migratory capacity.[4]

Exosomal RNA transfer between cancer cells can propagate chemoresistance phenotypes.[5]

## Radiotherapy-Specific Resistance Mechanisms

**Enhanced DNA repair capacity** is the primary radiotherapy-specific resistance mechanism. Radioresistant cells demonstrate **higher DNA repair potential** with altered levels of DNA repair proteins including pATM, KU70, and RAD51.[6]

Drug-resistant cells that are cross-resistant to radiation show lower levels of γH2AX foci upon irradiation, indicating more efficient DNA damage repair.[6] **P4HA2 (Prolyl 4-Hydroxylase Subunit Alpha 2)** is specifically upregulated in radioresistant cells and promotes resistance through enhanced stemness and DNA damage repair; its knockdown synergizes with radiotherapy.[7]

Radioresistant cells harbor **DNA polymerases with significantly low fidelity** , seemingly sacrificing specificity to gain higher survival potential.[6] **TGF-β signaling** plays a unique role in radioresistance. Irradiated breast cancer cells show increased expression of TGF-β isoforms (β1, β2, β3) and their receptors (TGF-βR1, TGF-βR2), which mediate both proliferation and apoptosis resistance.[8]

This pathway drives a **hybrid epithelial-mesenchymal phenotype** specifically in radioresistant cells.[8] **Cancer stem cell enrichment** appears more prominent in radioresistance. Radiation exposure induces stem cell-like properties in non-stem cells, with radioresistant populations showing increased expression of Oct4, Sox2, Nanog, aldehyde dehydrogenase activity, and CD44+/CD24- populations.[9][8]

Treatment with TGF-βRI inhibitors can abrogate radiation-induced proliferation increases.[8]

## Overlapping Mechanisms While some mechanisms overlap—including

**TP53 mutations, BRCA1/BRCA2 alterations, interferon-stimulated genes, and general cancer stem cell properties**—the specific molecular pathways and their relative importance differ between chemotherapy and radiotherapy resistance.[10][11][12]

The tumor microenvironment contributes to both, but through distinct mechanisms: immune cell infiltration patterns differ, and hypoxia affects radiotherapy more directly than chemotherapy.[13][14]

Would you like me to summarize the latest therapeutic strategies or agents that specifically target these unique resistance mechanisms in breast cancer, such as inhibitors of ABC transporters for chemotherapy resistance or modulators of DNA repair pathways and TGF-β signaling for radiotherapy resistance?



### References
1. Recent Strategies to Overcome Breast Cancer Resistance. Khan MM, Yalamarty SSK, Rajmalani BA, Filipczak N, Torchilin VP . Critical Reviews in Oncology/Hematology. 2024;197:104351. doi:10.1016/j.critrevonc.2024.104351.
2. Drug Resistance in Breast Cancer: Mechanisms and Strategies for Management. Wu GY , Xiao MZ, Hao WC, et al. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 2025;83:101288. doi:10.1016/j.drup.2025.101288.
3. Decoding the Key Hallmarks of Chemoresistance: A Proteomic Tale From Breast Cancer Research. Bhavsar PP , Kalita B, Taunk K, Rapole S. Biochimica Et Biophysica Acta. Reviews on Cancer. 2025;:189404. doi:10.1016/j.bbcan.2025.189404.
4. New Advances in the Research of Resistance to Neoadjuvant Chemotherapy in Breast Cancer. An J, Peng C, Tang H, Liu X, Peng F . International Journal of Molecular Sciences. 2021;22(17):9644. doi:10.3390/ijms22179644.
5. The Underlying Mechanisms and Emerging Strategies to Overcome Resistance in Breast Cancer. Kannan K, Srinivasan A, Kannan A, Ali N. Cancers. 2025;17(17):2938. doi:10.3390/cancers17172938.
6. Molecular Mechanisms of Radiation Resistance in Doxorubicin-Resistant Breast Adenocarcinoma Cells. Luzhna L, Golubov A, Ilnytskyy S, Chekhun VF , Kovalchuk O. International Journal of Oncology. 2013;42(5):1692-
708. doi:10.3892/ijo.2013.1845.
7. Single-Cell and Spatial Transcriptomics Reveal P4ha2-Mediated Radiotherapy Resistance Mechanisms in Breast Cancer. Li H, Liu J, Jiao Y , et al. Theranostics. 2026;16(5):2192-2220. doi:10.7150/thno.121257.
8. Radio Resistance in Breast Cancer Cells Is Mediated Through TGF-β Signalling, Hybrid Epithelial-Mesenchymal Phenotype and Cancer Stem Cells. Yadav P , Shankar BS. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2019;111:119-130. doi:10.1016/j.biopha.2018.12.055.
9. Determinants of Resistance to Chemotherapy and Ionizing Radiation in Breast Cancer Stem Cells. Pavlopoulou A, Oktay Y , Vougas K, et al. Cancer Letters. 2016;380(2):485-493. doi:10.1016/j.canlet.2016.07.018.
10. P53-Dependent Cytoprotective Mechanisms Behind Resistance to Chemo-Radiotherapeutic Agents Used in Cancer Treatment. Krishnaraj J, Yamamoto T, Ohki R. Cancers. 2023;15(13):3399. doi:10.3390/cancers15133399.
11. The Molecular Basis of Radiosensitivity and Chemosensitivity in the Treatment of Breast Cancer. Xia F , Powell SN. Seminars in Radiation Oncology. 2002;12(4):296-304. doi:10.1053/srao.2002.35250.
12. Interferon-Stimulated Genes Are Involved in Cross-Resistance to Radiotherapy in Tamoxifen-Resistant Breast Cancer. Post AEM, Smid M, Nagelkerke A, et al. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. 2018;24(14):3397-3408. doi:10.1158/1078-0432.CCR-17-2551.
13. Emerging Mechanisms of Triple-Negative Breast Cancer Radioresistance: Interplay Between Cancer Cell Mechanisms and the Tumor Immune Microenvironment. Canha-Borges A, Nunes B, Quintas ST, et al. Cancer Treatment Reviews. 2025;140:103026. doi:10.1016/j.ctrv.2025.103026.
14. The Molecular Mechanisms Underlying the Therapeutic Resistance of Cancer Stem Cells. Kim JK, Jeon HY , Kim H. Archives of Pharmacal Research. 2015;38(3):389-401. doi:10.1007/s12272-014-0531-1. 4.